The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Biology Consortium, 2017The Role of Variations in the LRRK2 Gene in Parkinson's Disease
Study Rationale:
Genes can influence one's chance of developing Parkinson's disease (PD), but it's not entirely clear how. In this study, we will use cells from people with Parkinson's to test how the... -
Mitochondrial Biomarkers Program, 2018Studying the Production of Mitochondria to Find New Therapeutic Targets for Parkinson's Disease
Study Rationale:
It is known that the brain cells damaged in Parkinson's disease (PD) struggle to generate energy. This is because mitochondria -- powerhouses of the cell -- are faulty in these cells... -
Access to Data and Biospecimens, 2017LRRK2 in predicting Parkinson disease risk and progression in LRRK2 mutation carriers
Study Rationale:
The G2019S mutation in the LRRK2 gene is responsible for thousands Parkinson disease (PD) cases. But, not all of the mutation carriers will develop PD. Currently, clinicians...
-
Therapeutic Pipeline Program, 2018Disease-modifying Glucocerebrosidase Therapy for Parkinson's Disease
Study Rationale:
Many people with Parkinson's disease (PD) have an abnormal glucocerebrosidase (GBA) enzyme, which causes them to accumulate fatty acids -- chemicals that make up fat -- in the brain... -
Mitochondrial Biomarkers Program, 2018N-formyl Peptides as Novel Biomarkers for Parkinson's Disease
Study Rationale:
Mitochondria -- the powerhouses of the cell -- have their own DNA that contains the instructions to make thirteen proteins. Fragments of these proteins, known as N-formyl peptides... -
Target Advancement Program, 2018Searching for and Targeting Calcium Channels that Control Alpha-synuclein Release
Study Rationale:
Being the primary component of Lewy bodies -- protein clumps that are the pathological hallmark of Parkinson's disease (PD) -- the protein alpha-synuclein plays the central role in PD...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.